NASDAQ:ZEAL
Delisted
Zealand Pharma Stock News
$17.59
+0 (+0%)
At Close: Jan 27, 2023
Zealand Pharma to seek FDA approval of its treatment for rare genetic disorder in babies
08:48am, Thursday, 19'th May 2022
U.S.-listed shares of Zealand Pharma ZEAL, +1.83% ZEAL, +18.99% soared 21.2% in premarket trading on Thursday after the company said a Phase 3 clinical trial evaluating its investigational treatment f
Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q1 2022 Earnings Call Transcript
04:06pm, Thursday, 12'th May 2022
Zealand Pharma A/S (ZEAL) Q1 2022 Earnings Conference Call May 12, 2022 10:00 AM ET Company Participants Matt Dallas - SVP and CFO Adam Steensberg - President and CEO Conference Call Participants Thom
Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10am ET) to Present First Quarter Results for 2022
04:00am, Thursday, 05'th May 2022
Company announcement – No. 15 / 2022
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2021 Results - Earnings Call Transcript
08:24pm, Thursday, 10'th Mar 2022 Seeking AlphaZealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2021 Results - Earnings Call Transcript
03:24pm, Thursday, 10'th Mar 2022
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2021 Results - Earnings Call Transcript
Zealand Pharma A/S 2021 Q4 - Results - Earnings Call Presentation
03:21pm, Thursday, 10'th Mar 2022 Seeking AlphaZealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021
04:00am, Thursday, 03'rd Mar 2022
Company announcement – No. 6 / 2022
Zeal Technology Unveils Its Digital Adoption Platform for the iPad
01:42pm, Thursday, 24'th Feb 2022 Kwhen FinanceZealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study
01:52pm, Friday, 21'st Jan 2022
Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.
Zealand Pharma A/S (NASDAQ:ZEAL) Stock Price Up 5.5%
05:46pm, Wednesday, 15'th Dec 2021 Dakota Financial News
Zealand Pharma A/S (NASDAQ:ZEAL)s stock price rose 5.5% during trading on Wednesday . The stock traded as high as $21.88 and last traded at $21.88. Approximately 228 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 16,498 shares. The stock had previously closed at $20.73. Separately, Zacks Investment []
Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Up to $21.30
08:16am, Sunday, 28'th Nov 2021 ETF Daily News
Zealand Pharma A/S (NASDAQ:ZEAL)s stock price gapped up prior to trading on Friday . The stock had previously closed at $21.30, but opened at $22.00. Zealand Pharma A/S shares last traded at $22.00, with a volume of 9 shares changing hands. Separately, Zacks Investment Research upgraded shares of Zealand Pharma A/S from a sell rating [] The post Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Up to $21.30 appeared first on ETF Daily News .
Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Down to $23.15
05:58pm, Wednesday, 24'th Nov 2021 Dakota Financial News
Shares of Zealand Pharma A/S (NASDAQ:ZEAL) gapped down before the market opened on Monday . The stock had previously closed at $23.15, but opened at $22.07. Zealand Pharma A/S shares last traded at $22.07, with a volume of 100 shares traded. Separately, Zacks Investment Research raised Zealand Pharma A/S from a sell rating to a []
Zealand Pharma A/S (NASDAQ:ZEAL) Hits New 52-Week Low at $22.33
10:24am, Sunday, 21'st Nov 2021 Transcript Daily
Zealand Pharma A/S (NASDAQ:ZEAL) reached a new 52-week low during trading on Friday . The stock traded as low as $22.33 and last traded at $23.15, with a volume of 1600 shares. The stock had previously closed at $23.09. Separately, Zacks Investment Research raised Zealand Pharma A/S from a sell rating to a hold rating []
Zacks Investment Research Upgrades Zealand Pharma A/S (NASDAQ:ZEAL) to Hold
08:40am, Friday, 19'th Nov 2021 Transcript Daily
Zealand Pharma A/S (NASDAQ:ZEAL) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, []
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2021 Results - Earnings Call Transcript
04:17pm, Thursday, 11'th Nov 2021
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2021 Results - Earnings Call Transcript